Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK9 | P50750 | 18/20 | 1.00 |
| ▸ | CCNT1 | O60563 | 17/20 | 1.00 |
| ▸ | MAP4K4 | O95819 | 2/20 | 1.00 |
| ▸ | CDK1 | P06493 | 2/20 | 1.00 |
| ▸ | CDK4 | P11802 | 2/20 | 1.00 |
| ▸ | CCNB1 | P14635 | 2/20 | 1.00 |
| ▸ | CCND1 | P24385 | 2/20 | 1.00 |
| ▸ | ABL2 | P42684 | 2/20 | 1.00 |
| ▸ | GSK3A | P49840 | 2/20 | 1.00 |
| ▸ | CDK7 | P50613 | 2/20 | 1.00 |
| ▸ | CCNH | P51946 | 2/20 | 1.00 |
| ▸ | MNAT1 | P51948 | 2/20 | 1.00 |
| ▸ | CDK2 | P24941 | 2/20 | 1.00 |
| ▸ | CCNA2 | P20248 | 1/20 | 1.00 |
| ▸ | CCNA1 | P78396 | 1/20 | 1.00 |
| ▸ | CDK5 | Q00535 | 1/20 | 1.00 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4430368 | 1.00 | CDK9 (1.00) | CDK9CCNT1MAP4K4CDK1CDK4 | |
| SCHEMBL4427553 | 0.92 | CDK9 (0.85) | CDK9CCNT1MAP4K4CDK1CDK4 | |
| SCHEMBL4430596 | 0.91 | CCNT1 (0.83) | CDK9CCNT1MAP4K4CDK1CDK4 | |
| SCHEMBL8514632 | 0.91 | CDK9 (0.83) | CDK9CCNT1MAP4K4CDK1CDK4 | |
| SCHEMBL4426442 | 0.90 | CDK9 (0.82) | CDK9CCNT1MAP4K4CDK1CDK4 | |
| SCHEMBL8515451 | 0.90 | CCNT1 (0.82) | CDK9CCNT1MAP4K4CDK1CDK4 | |
| SCHEMBL2997322 | 0.90 | CDK9 (0.81) | CDK9CCNT1MAP4K4CDK1CDK4 | |
| SCHEMBL4424917 | 0.89 | CCNT1 (0.80) | CDK9CCNT1MAP4K4CDK1CDK4 | |
| SCHEMBL4438737 | 0.89 | CDK9 (0.80) | CDK9CCNT1MAP4K4CDK1CDK4 | |
| SCHEMBL4426584 | 0.89 | CCNT1 (0.80) | CDK9CCNT1MAP4K4CDK1CDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 111 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4529926-A1 | METHOD FOR TREATING CANCER BY COMBINING ALKYLATING AGENT PRODRUG AND CELL CYCLE INHIBITOR | Ascentawits Pharmaceuticals, Ltd. (CN) | 2025-04-02 | — | — | EP | claimed |
| WO-2025051337-A1 | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING ORAL CANCER | Afyx Development A/S (DK) | 2025-03-13 | — | — | WO | claimed |
| US-20250057963-A1 | DISCOVERY OF PIPERLONGUMINE AS A NOVEL E3 LIGASE LIGAND | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2025-02-20 | — | — | US | claimed |
| CN-119233822-A | Methods of treating cancer using alkylating agent prodrugs and cell cycle inhibitors in combination | 深圳艾欣达伟医药科技有限公司 | 2024-12-31 | — | — | CN | claimed |
| US-20240390382-A1 | METHOD FOR TREATING CANCER | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2024-11-28 | — | — | US | claimed |
| US-12024715-B2 | Compositions and methods for improved T cells | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2024-07-02 | — | — | US | claimed |
| CN-117919247-A | Application of LDC000067 in preparation of medicine for treating influenza virus infection | 暨南大学 | 2024-04-26 | — | — | CN | claimed |
| WO-2023226959-A1 | METHOD FOR TREATING CANCER BY COMBINING ALKYLATING AGENT PRODRUG AND CELL CYCLE INHIBITOR | 深圳艾欣达伟医药科技有限公司 | 2023-11-30 | — | — | WO | claimed |
| CN-112351819-B | Method for treating malignant lymphoproliferative diseases | 开动疗法公司 | 2023-11-10 | — | — | CN | claimed |
| US-20230293414-A1 | USE OF CYCLIN-DEPENDENT KINASE (CDK) INHIBITORS FOR THE SLOWDOWN OR PREVENTION OF BIOLOGICAL AGING | HOPE PERMANENTE LLC (US) | 2023-09-21 | — | — | US | claimed |
| WO-2023114455-A1 | DISCOVERY OF PIPERLONGUMINE AS A NOVEL E3 LIGASE LIGAND | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2023-06-22 | — | — | WO | claimed |
| US-20230183323-A1 | METHODS FOR PREVENTING, REVERSING OR TREATING A COVID-19 INFECTION | BROWN UNIVERSITY | 2023-06-15 | — | — | US | claimed |
| EP-4192463-A1 | USE OF CYCLIN-DEPENDENT KINASE (CDK) INHIBITORS FOR THE SLOWDOWN OR PREVENTION OF BIOLOGICAL AGING | Hope Permanente, LLC (US) | 2023-06-14 | — | — | EP | claimed |
| WO-2023055641-A2 | METHOD FOR TREATING CANCER | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2023-04-06 | — | — | WO | claimed |
| US-20230035479-A1 | METHODS AND COMPOSITIONS FOR REDUCING HAIR GREYING | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2023-02-02 | — | — | US | claimed |
| US-11510904-B2 | Methods of treating malignant lymphoproliferative disorders | ACTUATE THERAPEUTICS INC. (US) | 2022-11-29 | — | — | US | claimed |
| US-11452716-B2 | Pharmaceutical composition and use thereof | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2022-09-27 | — | — | US | claimed |
| EP-4048809-B1 | SYSTEMS AND METHODS FOR PREDICTING THERAPEUTIC SENSITIVITY | TEMPUS AI INC (US) | 2026-05-27 | — | — | EP | disclosed |
| US-11324827-B2 | Multifunctionalized polyethylene glycol derivative and preparation method therefor | XIAMEN SINOPEG BIOTECH CO., LTD. (CN) | 2022-05-10 | — | — | US | disclosed |
| WO-2022046650-A1 | COMBINATION THERAPIES WITH OLIG2 INHIBITORS | Curtana Pharmaceuticals, Inc. (US) | 2022-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11510904-B2 | Methods of treating malignant lymphoproliferative disorders | PPM1B, ING2, BCL9 | CDK9 53/4885CCNT1 1021/4885MAP4K4 267/4885 |
| US-20240390382-A1 | METHOD FOR TREATING CANCER | ELL, ELOB, ELP1 | CDK9 726/4885CCNT1 1285/4885MAP4K4 3453/4885 |
| US-11452716-B2 | Pharmaceutical composition and use thereof | TP53, RB1, CDK20 | CDK9 8/4885CCNT1 47/4885MAP4K4 387/4885 |
| US-20250057963-A1 | DISCOVERY OF PIPERLONGUMINE AS A NOVEL E3 LIGASE LIGAND | CDK10, CDK20, CDK9 | CDK9 3/4885CCNT1 48/4885MAP4K4 434/4885 |
| US-20230183323-A1 | METHODS FOR PREVENTING, REVERSING OR TREATING A COVID-19 INFECTION | CHI3L1, CHI3L2, ACE2 | CDK9 4498/4885CCNT1 4791/4885MAP4K4 2816/4885 |
| US-11324827-B2 | Multifunctionalized polyethylene glycol derivative and preparation method therefor | HDGF, F11, F12 | CDK9 4147/4885CCNT1 25/4885MAP4K4 4528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.